Q-omics provides the consensus-scored MED18 profile across patient tissues and cancer cell-line models. MED18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MED18 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, MED18 protein abundance shows 23,541 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, KICH, and GBM as cancer lineages where MED18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED18 survival associations across molecular data types. MED18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED18 RNA expression–survival associations across cancer types. High MED18 expression shows unfavorable associations in LIHC, LGG and LAML, but favorable associations in COAD, STAD and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for MED18 RNA expression.
This table summarizes MED18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MED18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED18 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, BRCA, BLCA and LUAD. The KICH box plot shows higher MED18 RNA expression in normal versus tumor tissue (log2 FC = −1.402, t-test p < 0.001).
This table shows molecular features associated with MED18 in patient tissues and cancer cell lines. In patient samples, MED18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MED18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
